Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Quarterly Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB) released its quarterly earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02), Zacks reports. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the firm posted ($0.02) EPS. Y-mAbs Therapeutics updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $5.19 on Tuesday. The firm has a market cap of $232.45 million, a PE ratio of -9.61 and a beta of 0.67. Y-mAbs Therapeutics has a 12 month low of $5.13 and a 12 month high of $19.12. The firm has a 50 day simple moving average of $6.58 and a 200 day simple moving average of $10.72.

Analysts Set New Price Targets

YMAB has been the topic of several analyst reports. Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday. Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.